|
|
|
|
|
Twitter
JanssenUS NSCLC, JCO, lcsm, EGFR: 03/08/2021 14:30:08
|
|
|
|
Data evaluating a targeted therapy in patients with #NSCLC with epidermal growth factor receptors with exon 20 insertion mutations has been published in @ASCO_pubs #JCO. Read more here: https://t.co/Zr1cSehzEx #lcsm #EGFR
Read more
|
|
|
|
|
|
|
|
|
Twitter
PeerView immunotherapy, NSCLC, ASCO21, LCSM: 03/08/2021 18:01:05
|
|
|
|
In this engaging video, Jamie E. Chaft, MD (@ChaftJamie) and Jonathan D. Spicer, MD, PhD, FRCSC (@DoctorJSpicer) discuss the evolving role of #immunotherapy in stage I-III #NSCLC. Catch up on the exciting advances now!
Read more
|
|
|
|
|
|
|
|
|
Twitter
Paperbirds_Oncology lungcancer, oncology: 03/08/2021 17:22:35
|
|
|
|
New clinical trial: Osimertinib Plus Bevacizumab in Untreated EGFR Exon21 L858R Mutated NSCLC https://t.co/b7kqvL9Z6h #lungcancer #oncology
Read more
|
|
|
|
|
|
|
|
|
Twitter
Oncology Publishers Feed Oncology, MedTwitter, MedEd: 03/08/2021 19:11:02
|
|
|
|
KRAS Inhibitors, Immunotherapy, and ADCs Carve Out Newfound Applications in NSCLC
More medical news at https://t.co/DUWSlWzJcW
#Oncology #MedTwitter #MedEd
Read more
|
|
|
|
|
|
|
|
|
Twitter
OncLive.com : 03/08/2021 20:40:25
|
|
|
|
KRAS Inhibitors, Immunotherapy, and ADCs Carve Out Newfound Applications in NSCLC @MLJohnsonMD2 @SarahCannonDocs @ASCO #ASCO21#lcsm
Read more
|
|
|
|
|
|
|
|
|
Twitter
OncLive.com ILCC2021, lcsm: 03/08/2021 22:00:29
|
|
|
|
WATCH: @PatelOncology, of @UCSDHealth, discusses the potential of combining PARP inhibitors with immunotherapy for patients with non–small cell lung cancer @gotoPER #ILCC2021 #lcsm
Read more
|
|
|
|
|
|
|
|
|
Twitter
Frontiers in Immunology immunology: 03/08/2021 23:57:02
|
|
|
|
New Research: Case Report: Abscopal Effect of Microwave Ablation in a Patient With Advanced Squamous NSCLC and Resistance to Immunotherapy: Currently, immunotherapy has been a backbone in the treatment of advanced non-small cell lung cancer…
Read more
|
|
|
|
|
|
|
|
|
Twitter
OncLive.com ILCC2021, lcsm: 04/08/2021 02:00:14
|
|
|
|
Utility of Immunotherapy Keeps Evolving in Unresectable Stage III NSCLC @EnriquetaFelip @vallhebron @gotoPER #ILCC2021 #lcsm
Read more
|
|
|
|
|
|
|
|
|
Twitter
TrialBulletin : 04/08/2021 03:33:25
|
|
|
|
Osimertinib Plus Bevacizumab in Untreated EGFR Exon21 L858R Mutated NSCLC: Status: Not yet recruiting,
Condition Summary: Lung Cancer
Read more
|
|
|
|
|
